Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant-Reference-Cited by-同舟云学术

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant

Published:2020-02-04 Issue:7 Volume:34 Page:1898-1906
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Aziz Mina D.,Shah Jay,Kapoor Urvi,Dimopoulos Christina,Anand Sarah,Augustine Allan,Ayuk Francis,Chaudhry Mohammed,Chen Yi-Bin^ORCID,Choe Hannah K.,Etra Aaron,Gergoudis Stephanie,Hartwell Matthew J.,Hexner Elizabeth O.,Hogan William J.^ORCID,Kitko Carrie L.,Kowalyk Steven,Kröger Nicolaus,Merli Pietro,Morales George,Nakamura Ryotaro,Ordemann Rainer,Pulsipher Michael A.,Qayed Muna,Reshef Ran,Rösler Wolf,Schechter Tal,Schreiner Elisabeth,Srinagesh Hrishikesh,Wölfl Matthias,Wudhikarn Kitsada,Yanik Gregory,Young Rachel,Özbek Umut,Ferrara James L. M.,Levine John E.

Funder

Doris Duke Charitable Foundation

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0726-z.pdf

Reference44 articles.

1. Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379:2330–41.

2. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–61.

3. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.